Illumina's New Constellation Technology Outperforms Traditional Methods in GeneDx Clinical Study for Rare Disease Genomics

Reuters

2025/10/15

<a href="https://laohu8.com/S/ILMN">Illumina</a>'s New <a href="https://laohu8.com/S/CEG">Constellation</a> Technology Outperforms Traditional Methods in GeneDx Clinical Study for Rare Disease Genomics

Illumina Inc. has announced that Joe Devaney will present the results of GeneDx's expanded, 160-sample study involving Illumina's Constellation technology at the ASHG Annual Meeting in Boston. The presentation, titled "Mapping the Future of Whole Genome Sequencing with Illumina Constellation Technology," is scheduled for October 15 and will take place in Room 153ABC from 12:00 PM to 1:00 PM ET. According to Illumina, the Constellation mapped read technology demonstrated improved accuracy, speed, and ease of use in identifying difficult-to-map genomic variants, outperforming orthogonal methods in this pilot study. Results have not yet been presented and will be disclosed at the upcoming conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA98369) on October 15, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2575780934"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575780934\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575780934?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-15 21:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575780934","market":"nz","top_or_hot":-1,"title":"Illumina's New Constellation Technology Outperforms Traditional Methods in GeneDx Clinical Study for Rare Disease Genomics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ILMN\">Illumina</a>'s New <a href=\"https://laohu8.com/S/CEG\">Constellation</a> Technology Outperforms Traditional Methods in GeneDx Clinical Study for Rare Disease Genomics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ILMNV\">Illumina Inc</a>. has announced that Joe Devaney will present the results of GeneDx's expanded, 160-sample study involving Illumina's Constellation technology at the ASHG Annual Meeting in Boston. The presentation, titled \"Mapping the Future of Whole Genome Sequencing with Illumina Constellation Technology,\" is scheduled for October 15 and will take place in Room 153ABC from 12:00 PM to 1:00 PM ET. According to Illumina, the Constellation mapped read technology demonstrated improved accuracy, speed, and ease of use in identifying difficult-to-map genomic variants, outperforming orthogonal methods in this pilot study. Results have not yet been presented and will be disclosed at the upcoming conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA98369) on October 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina's New Constellation Technology Outperforms Traditional Methods in GeneDx Clinical Study for Rare Disease Genomics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina's New Constellation Technology Outperforms Traditional Methods in GeneDx Clinical Study for Rare Disease Genomics\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-15 21:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ILMN\">Illumina</a>'s New <a href=\"https://laohu8.com/S/CEG\">Constellation</a> Technology Outperforms Traditional Methods in GeneDx Clinical Study for Rare Disease Genomics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ILMNV\">Illumina Inc</a>. has announced that Joe Devaney will present the results of GeneDx's expanded, 160-sample study involving Illumina's Constellation technology at the ASHG Annual Meeting in Boston. The presentation, titled \"Mapping the Future of Whole Genome Sequencing with Illumina Constellation Technology,\" is scheduled for October 15 and will take place in Room 153ABC from 12:00 PM to 1:00 PM ET. According to Illumina, the Constellation mapped read technology demonstrated improved accuracy, speed, and ease of use in identifying difficult-to-map genomic variants, outperforming orthogonal methods in this pilot study. Results have not yet been presented and will be disclosed at the upcoming conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA98369) on October 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票月供概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL9QmmlH:1","article_id":"2575780934","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575780934","pubTimestamp":1760534206,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Illumina Inc. has announced that Joe Devaney will present the results of GeneDx's expanded, 160-sample study involving Illumina's Constellation technology at the ASHG Annual Meeting in Boston. The presentation, titled \"Mapping the Future of Whole Genome Sequencing with Illumina Constellation Technology,\" is scheduled for October 15 and will take place in Room 153ABC from 12:00 PM to 1:00 PM ET. According to Illumina, the Constellation mapped read technology demonstrated improved accuracy, speed, and ease of use in identifying difficult-to-map genomic variants, outperforming orthogonal methods in this pilot study. Results have not yet been presented and will be disclosed at the upcoming conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","ILMN":"Illumina","BK4548":"巴美列捷福持仓","BK4534":"瑞士信贷持仓","BK4535":"淡马锡持仓","CT1.AU":"Constellation Technologies Ltd","BK4121":"生命科学工具和服务","BK7084":"电子设备和仪器"},"translate_title":"Illumina新Constellation技术在罕见病基因组学GeneDx临床研究中优于传统方法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CT1.AU":0.9,"ILMN":0.9},"content_text":"Illumina's New Constellation Technology Outperforms Traditional Methods in GeneDx Clinical Study for Rare Disease Genomics\n    \n\nIllumina Inc. has announced that Joe Devaney will present the results of GeneDx's expanded, 160-sample study involving Illumina's Constellation technology at the ASHG Annual Meeting in Boston. The presentation, titled \"Mapping the Future of Whole Genome Sequencing with Illumina Constellation Technology,\" is scheduled for October 15 and will take place in Room 153ABC from 12:00 PM to 1:00 PM ET. According to Illumina, the Constellation mapped read technology demonstrated improved accuracy, speed, and ease of use in identifying difficult-to-map genomic variants, outperforming orthogonal methods in this pilot study. Results have not yet been presented and will be disclosed at the upcoming conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA98369) on October 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}